Compass Pathways announced the initiation of the UK component of its phase 3 program of investigational COMP360 psilocybin treatment in treatment-resistant depression, or TRD. The research will take place in multiple sites in the UK, including at the Centre for Mental Health Research and Innovation in London, which officially opened. The ongoing phase 3 program is the largest randomized, controlled, double-blind psilocybin treatment clinical program ever conducted and follows results from Compass’s phase 2b study of COMP360 psilocybin treatment. The phase 3 program consists of two pivotal trials and each trial has an integrated, long-term outcomes component. COMP 006 will take place in the UK and globally and will study three dose arms of COMP360. COMP 005 is a US-based trial examining the effect of a single 25mg dose of COMP360 psilocybin, compared with placebo.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CMPS:
- Compass Pathways initiates UK component of global phase 3 study of psilocybin treatment in treatment-resistant depression and launches new research center
- Rising High: Exclusive talk with coca leaf company Harbour Coca
- Rising High: Exclusive talk with venture capital firm Safe Supply
- COMPASS Pathways Announces Third Quarter 2023 Financial Results and Business Highlights
- Compass Pathways reports Q3 EPS (67c), consensus (43c)